Abstract: An embodiment humidity sensor device includes a humidity sensor including a measurement section for measuring humidity, a housing accommodating the humidity sensor while the measurement section is exposed to the outside, and a wall member protruding from a bottom surface of the housing and surrounding a periphery of the measurement section.

Abstract: A wearable device includes a sensor device and a clothes to which the sensor device is attached. The clothes includes a clothes body and an insertion and extraction portion that has an opening formed in the clothes body and enables the sensor device to be inserted into or extracted from the clothes body. The sensor device includes a humidity sensor configured to measure humidity in the clothes body and a housing having a first region exposed to an inside of the clothes body and a second region exposed to an outside of the clothes body, while the sensor device is inserted from the insertion and extraction portion into the clothes body. The humidity sensor is accommodated in the first region of the housing.

Abstract: It has become clear that the therapeutic effect of an IL-6 inhibitor for IL-6- and neutrophil-associated diseases can be predicted using the expression level of neutrophil-associated genes as an indicator. It has also become clear that an IL-6 inhibitor is effective for the treatment of IL-6- and neutrophil-associated diseases in patients with high expression levels of neutrophil-associated genes. The present invention provides a method for selecting cases of IL-6- and neutrophil-associated diseases in which treatment with an IL-6 inhibitor is effective, as well as a method for effectively treating patients with IL-6- and neutrophil-associated diseases and with high expression levels of neutrophil-associated genes.

Abstract: It has become clear that the therapeutic effect of an IL-6 inhibitor for IL-6- and neutrophil-associated diseases can be predicted using the expression level of neutrophil-associated genes as an indicator. It has also become clear that an IL-6 inhibitor is effective for the treatment of IL-6- and neutrophil-associated diseases in patients with high expression levels of neutrophil-associated genes. The present invention provides a method for selecting cases of IL-6- and neutrophil-associated diseases in which treatment with an IL-6 inhibitor is effective, as well as a method for effectively treating patients with IL-6- and neutrophil-associated diseases and with high expression levels of neutrophil-associated genes.

Abstract: It has become clear that the therapeutic effect of an IL-6 inhibitor for IL-6- and neutrophil-associated diseases can be predicted using the expression level of neutrophil-associated genes as an indicator. It has also become clear that an IL-6 inhibitor is effective for the treatment of IL-6- and neutrophil-associated diseases in patients with high expression levels of neutrophil-associated genes. The present invention provides a method for selecting cases of IL-6- and neutrophil-associated diseases in which treatment with an IL-6 inhibitor is effective, as well as a method for effectively treating patients with IL-6- and neutrophil-associated diseases and with high expression levels of neutrophil-associated genes.

Abstract: A hair-growing agent comprising, as active ingredients, one or more members selected from the group consisting of lysophosphatidic acids, and phosphatidic acids wherein the fatty acid residue moiety consists only of straight-chain fatty acid residues having an even number of carbon atoms.

Abstract: A hair-growing agent comprising, as active ingredients, one or more members selected from the group consisting of lysophosphatidic acids, and phosphatidic acids wherein the fatty acid residue moiety consists only of straight-chain fatty acid residues having an even number of carbon atoms.

Abstract: The present invention relates to a process for purifying dimeric to pentameric proanthocyanidin oligomers which comprises extracting the proanthocyanidin oligomers from raw materials containing the proanthocyanidin oligomers or crude purification products therefrom by solid-liquid extraction using methyl acetate as a liquid phase; a process for purifying dimeric to pentameric proanthocyanidin oligomers which comprises pretreating with an enzyme for hydrolysis raw materials containing the proanthocyanidin oligomers, crude purification products therefrom, or a solution containing one of these; and a process for purifying dimeric to pentameric proanthocyanidin oligomers with a uniform polymerization degree which comprises separating and purifying the proanthocyanidin oligomers by polymerization degree from raw materials containing the proanthocyanidin oligomers or crude purification products there from by normal phase silica gel liquid chromatography using as a mobile phase a single solvent or a mixed solvent of